FREMONT, Calif.--(BUSINESS WIRE)--Shockwave Medical, a pioneer in the treatment of advanced peripheral and coronary vascular disease, today announced CE Mark regulatory approval for the company’s ...

LAS VEGAS — A lithoplasty device was associated with positive 6-month outcomes in patients with symptomatic calcified femoropopliteal lesions, according to the results of the DISRUPT PAD study. The ...

FREMONT, Calif. & LONDON., Shockwave Medical, a pioneer in the treatment of calcified vascular disease, today announced positive clinical results from the pooled DISRUPT PAD Study, a single-arm, ...

FREMONT, CA — The US Food and Drug Administration has approved Shockwave Medical's Lithoplasty System as treatment for calcified plaque in patients with peripheral artery disease, the company ...

FREMONT, Calif., Shockwave Medical, a pioneer in the treatment of calcified cardiovascular disease, today announced clearance from the U.S. Food and Drug Administration (FDA) of the Lithoplasty ® ...

A rendering of the Lithoplasty balloon catheter, screenshot--Courtesy of Shockwave Medical Medical device makers are scrambling to develop and sell advanced angioplasty balloons to treat peripheral ...

A rendering of the Lithoplasty balloon catheter, screenshot--Courtesy of Shockwave Medical Startup Shockwave Medical expects that its Lithoplasty balloon catheters will emerge as a pretreatment for ...

Bay Area device startup Shockwave Medical just raised $40 million to build out its balloon catheters to be used in peripheral, coronary and aortic valve surgeries. It uses the same basic technology ...

Please provide your email address to receive an email when new articles are posted on . Patients with CAD whose calcified plaque was treated with lithoplasty along with stenting had improved outcomes ...

Shockwave Medical, a pioneer in the treatment of calcified cardiovascular disease, today announced the closing of $45 million in Series C financing led by Sectoral Asset Management, with participation ...

Shockwave Medical Inc. raised $45 million in a series C round to further develop its Lithoplasty balloon catheter platform. Sectoral Asset Management led the funding round, joined by new backer T.